Rod Humerickhouse
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Acute Lymphoblastic Leukemia research, Chronic Myeloid Leukemia Treatments, Cancer Treatment and Pharmacology
Most-Cited Works
- → ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets(2013)2,976 cited
- → Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia(2015)1,861 cited
- → Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia(2016)1,040 cited
- → Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia(2018)888 cited
- → Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity(2010)845 cited
- → Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions(2019)829 cited
- → Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease(2011)811 cited
- → Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study(2016)786 cited
- → Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma(2017)745 cited
- → Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study(2018)700 cited